Asia-Pacific journal of clinical oncology最新文献

{"title":"Optimizing Digital Mental Health Interventions for Breast Cancer Survivors: Insights and Future Directions.","authors":"Pei-Chen Li, Lien-Chung Wei","doi":"10.1111/ajco.14213","DOIUrl":"https://doi.org/10.1111/ajco.14213","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14213"},"PeriodicalIF":1.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144537945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2025 ANZUP Annual Scientific Meeting, 20-22 July 2025. Hyatt Regency Sydney.","authors":"","doi":"10.1111/ajco.14216","DOIUrl":"https://doi.org/10.1111/ajco.14216","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 Suppl 2 ","pages":"1-119"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Longitudinal Observation of Lenvatinib-associated Adverse Events in Patients With Unresectable Radioiodine-refractory Differentiated Thyroid Cancer.","authors":"Yuka Aida, Toshio Suzuki, Yusuke Watanabe, Sachie Hashimoto, Emika Ichioka, Akiko Iguchi-Manaka, Joichi Usui, Masato Homma, Hisato Hara, Ikuo Sekine","doi":"10.1111/ajco.14211","DOIUrl":"https://doi.org/10.1111/ajco.14211","url":null,"abstract":"<p><strong>Aim: </strong>To characterize the long-term adverse events (AEs) observed in patients who received lenvatinib.</p><p><strong>Methods: </strong>We longitudinally assessed long-term AEs in patients with advanced or metastatic radioiodine-refractory differentiated thyroid cancer who had received lenvatinib for more than 1 year. AEs were graded according to the National Cancer Institute Common Terminology Criteria for AEs. Grade 2 AEs were defined as intolerable if a patient complained of distress.</p><p><strong>Results: </strong>Seventeen patients were treated for more than 1 year. The median age was 69 years. The median duration of lenvatinib treatment was 40 months. Notable intolerable grade 2 and 3 AEs were developed in the following order: hypertension (median day 18; range, day 1-131), diarrhea (median, day 27; range, day 4-1205), hand-foot skin reaction (median, day 33; range, day 20-582), platelet decrease (median, day 57; range, day 15-427), proteinuria (median, day 72; range, day 18-1772), anorexia (median, day 319; range, day 57-1541), and chronic kidney disease (CKD) (median, day 715; range, day 274-1296). After 2 years of administration, the decrease in estimated glomerular filtration rate became remarkable. Grade 3 hypertension occurred in 94.1% (16/17) of patients, of whom 66.8% (11/16) developed intolerable grade 2 proteinuria at a median interval of 35 days. Of these patients, 54.5% (6/11) developed intolerable grade 2 CKD at a median interval of 245 days.</p><p><strong>Conclusions: </strong>This longitudinal study revealed which AEs appeared and when. The findings provide useful information about when and which AEs we should be attentive to during daily practice.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14211"},"PeriodicalIF":1.4,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Multicenter Real-World Study of Outcomes in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with a Polatuzumab Vedotin-Based Regimen in a Compassionate Use Program in Malaysia.","authors":"S Fadilah Abdul Wahid, Nor Asiah Muhamad, Nor Azimah Ismail, Izzah Athirah Rosli, Chiang Su Kien, Soo Min Lim, Lee Ping Chew, Kirubamoorthy Kamini, Veena Selvaratnam, Ahlam Naila Kori, Teh Hiok Seng, Soo-Chin Ng","doi":"10.1111/ajco.14208","DOIUrl":"https://doi.org/10.1111/ajco.14208","url":null,"abstract":"<p><strong>Background: </strong>Polatuzumab vedotin + bendamustine + rituximab (Pola-BR) was recently approved in Malaysia for treating relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). A multicenter retrospective study was conducted to assess the effectiveness of this regimen among patients in a compassionate use program.</p><p><strong>Objective: </strong>To determine treatment response and survival rates for R/R DLBCL patients treated with Pola-BR in Malaysia.</p><p><strong>Methodology: </strong>Safety and efficacy data of 23 adults with R/R DLBCL treated with Pola-BR at nine centers in Malaysia (September 2019-February 2021) were used. Of the 23 patients, 13 received six cycles of Pola-BR. The median follow-up was 10 months (1-37 months). The primary endpoint was complete response (CR) rate; secondary endpoints were overall survival (OS), progression-free survival (PFS), and adverse events (AEs).</p><p><strong>Results: </strong>The overall response rate was 56.5%, with 34.8% achieving CR. The 1-, 2-, and 3-year OS rates were 51.6%, 51.6%, and 44.2%, respectively, with a median OS of 27 months. The 1- and 2-year PFS rates were 48.2% and 41.3%, respectively, with a median PFS of 10 months; 60% of the nonresponders had progressive disease. Cox proportional hazard regression analysis showed that bulky disease was a significant hazard for disease progression. A total of 42 AEs were recorded, of which 66.7% were grade ≥ 3 AEs; 90.5% of the AEs were hematological and resolved with treatment; only one patient succumbed to neutropenic sepsis.</p><p><strong>Conclusions: </strong>Pola-BR has a favorable safety profile for R/R DLBCL treatment in Malaysia, although larger sample sizes and longer follow-ups are needed to confirm these results.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14208"},"PeriodicalIF":1.4,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144504717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Impact of Synchronous and Metachronous Second Primary Cancers in Laryngeal Cancer Patients Treated With Radiotherapy: Variable With Time-Varying Effects and Cox Proportional Hazard Analyses.","authors":"Akikazu Kobori, Chiyoko Makita, Osamu Tanaka, Sunaho Okada, Yuichi Kajiura, Nansei Yamada, Masayuki Matsuo","doi":"10.1111/ajco.14206","DOIUrl":"https://doi.org/10.1111/ajco.14206","url":null,"abstract":"<p><strong>Aims: </strong>Patients with laryngeal and other head and neck cancers face a high risk of developing second primary cancers. This retrospective cohort study evaluated the prognostic value of second primary cancers in laryngeal cancer patients treated with radiotherapy.</p><p><strong>Methods: </strong>We retrospectively investigated patients with laryngeal cancer who underwent radiotherapy, and evaluated the incidence and relative risk of synchronous and metachronous second primary cancers in a single-institution cohort.</p><p><strong>Results: </strong>Between January 2007 and December 2021, 138 patients with laryngeal cancer were analyzed. The median follow-up period was 5.2 years. The 5-year overall survival rate was 82.4% and the progression-free survival rate was 71.9%. Synchronous and metachronous second primary cancers were observed in 15 (10.9%) and 38 (27.5%) patients, respectively, during the follow-up period. The cumulative incidence of metachronous second primary cancers was 23.3% at 5 years. Moreover, deaths from laryngeal cancer, other cancers, and noncancer illnesses accounted for 3.6% (5 patients), 12.3% (17 patients), and 10.9% (17 patients), respectively, with most deaths from causes other than laryngeal cancer occurring after the first 5 years. Synchronous second primary cancer was a significant prognostic factor of poor outcomes (hazard ratio, 4.42; 95% confidence interval, 1.93-10.13) on time-independent multivariate analysis, and metachronous second primary cancer was a significant prognostic factor of poor outcomes (hazard ratio, 4.55; 95% confidence interval, 2.09-9.91) in the time-dependent Cox proportional hazards model.</p><p><strong>Conclusion: </strong>Synchronous and metachronous second primary cancers are significant prognostic factors for patients with laryngeal cancer treated with radiotherapy.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14206"},"PeriodicalIF":1.4,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammation-Based Prognostication in Extensive-Stage Small Cell Lung Cancer in the First-Line Setting: The Advanced Lung Inflammation Index and the Others.","authors":"Erdoğan Selçuk Şeber, Ömer Faruk Elçiçek, Eyyüp Çavdar, Özge Yalıcı, Yıldız Garip Bilen, İlker Karaduman, Ezel Gedik, Okan Avcı","doi":"10.1111/ajco.14200","DOIUrl":"https://doi.org/10.1111/ajco.14200","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the prognostic significance of inflammatory indices, including the advanced lung inflammation index (ALI), in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line platinum-etoposide chemotherapy.</p><p><strong>Methods: </strong>The study included 167 ES-SCLC patients. Patients with confirmed ES-SCLC histology who had completed at least 2 months of first-line treatment (platinum etoposide chemotherapy regimen without immunotherapy) were included. Demographic information, clinicopathological characteristics, and blood parameters (blood test results between Days 1 and 7 before the first chemotherapy) of the patients before the first treatment were recorded from the electronic record system.</p><p><strong>Results: </strong>Median age was 62 years (range: 40-88 years). A total of 163 (97.6%) patients had died of cancer-related causes. For all patients, the median OS (mOS) was 9 (95% CI: 8-10) months. In univariate analysis, gender, age, smoking, BMI, brain metastasis status, bone metastasis status, PCI (prophylactic cranial irradiation), and SVCSS (superior vena cava syndrome) were not associated with survival. Poor performance status (p = 0.036), low C-reactive protein-albumin-lymphocyte index (CALLY) (p = 0.030), high systemic immune inflammation index (SII) (p = 0.042), and low ion index (ALI) (p = 0.016) were predictive of poor survival on univariate analysis. Factors found to be prognostic in univariate analysis were evaluated in multivariate analysis. In the established model, only ALI (HR = 0.68, 95% CI: 0.49-0.93, p = 0.016) were found to be an independent prognostic factor for OS. The corresponding mOS according to CALLY, SII, ALI, and ECOG (Eastern Cooperative Oncology Group - Performance score) performance status were 8 versus 10 months (p = 0.020), 10 versus 8 months (p = 0.030), 8 versus 9 months (p = 0.010), and 9 versus 8 months (p = 0.025), respectively, with significant difference.</p><p><strong>Conclusion: </strong>CALLY, SII, ALI, and ECOG performance status could be useful prognostic markers for clinicians in patients with ES-SCLC receiving chemotherapy, with ALI emerging as the strongest prognostic factor. These readily accessible and easily computed markers can facilitate cost-effective follow-up and treatment decision-making by providing clinicians with a real-time assessment of the dynamic balance between host immunity and tumor-associated inflammation.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14200"},"PeriodicalIF":1.4,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Survival Outcomes of Patients With High PD-L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy.","authors":"Junipearl Cheng, Charlotte McKay, Victoria Bray, Po Yee Yip, Annette Tognela, Peey Sei Kok","doi":"10.1111/ajco.14205","DOIUrl":"https://doi.org/10.1111/ajco.14205","url":null,"abstract":"<p><strong>Background: </strong>Randomized studies have demonstrated superior overall survival (OS) of pembrolizumab (pembro), both alone and in combination with chemotherapy (chemo) over chemo alone in patients with programmed cell death ligand-1 (PD-L1) ≥ 50% advanced non-small cell lung cancer (NSCLC). We reviewed the real-world outcomes of patients who received pembro-chemo versus pembro only.</p><p><strong>Methods: </strong>This Australian-based retrospective cohort study used data from patients with advanced NSCLC PD-L1 ≥ 50%, diagnosed between January 2016 and July 2021 and had received first-line pembro-chemo or pembro only. Patients with an EGFR/ALK/ROS1 sensitizing mutation were excluded. Cox proportional-hazards model and Kaplan-Meier methods were used to estimate OS and progression-free survival (PFS).</p><p><strong>Results: </strong>Of 111 eligible patients, 25 received pembro-chemo and 86 received pembro only. After a median follow-up of 15.7 months, median (95% CI) OS was not reached in the pembro-chemo group versus 15.6 (9.5-21.7) months in the pembro-only group (HR 0.57, 95% CI 0.28-1.16, p = 0.12). Median PFS was 12.4 (6.5-18.3) versus 9.5 (6.3-12.6) months in pembro-chemo versus pembro-only groups, respectively (HR 0.62, 95% CI 0.32-1.18, p = 0.18). Objective response rate (ORR) was higher in the pembro-chemo group (60% vs. 30.3%). There were more hospitalizations in the pembro-chemo group versus pembro-only group, 28% versus 18.6%, but immune-related adverse events were similar (32% vs. 32.6%).</p><p><strong>Conclusion: </strong>In patients with PD-L1 ≥ 50% advanced NSCLC, addition of chemo to first-line pembro yielded a higher ORR but no additional benefit in PFS or OS, supporting a shared-decision approach. However, higher rates of hospitalizations seen in the pembro-chemo group should warrant caution in use.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14205"},"PeriodicalIF":1.4,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Dawn-Using Teletrials for Early Phase Drug Development: A Practical Guideline.","authors":"G Gaughran, J Zalcberg, M Voskoboynik, M Shackleton","doi":"10.1111/ajco.14202","DOIUrl":"https://doi.org/10.1111/ajco.14202","url":null,"abstract":"<p><strong>Introduction: </strong>Access to early-phase cancer clinical trials is heavily skewed toward urban patients treated at tertiary centers, creating significant inequity for regional/rural (R/R) populations. For early drug development (EDD) trials, travel requirements are a major barrier to R/R participation. Growing public and governmental policy pressure on pharmaceutical stakeholders and trial centers has driven the exploration of innovative solutions to improve access. Among these, the teletrial model, which has been effective in later-phase studies, presents an opportunity to address recruitment challenges in phase 1 trials. This article provides practical guidelines for implementing teletrials in EDD.</p><p><strong>Methods/results: </strong>This review outlines key operational, regulatory, and logistical considerations for phase 1 teletrials, covering site evaluation, ethics and governance, resource allocation, and funding models. Several teletrial frameworks are presented, tailored to the varying capabilities of satellite sites and the complexities of early-phase trials. Lessons learned from successful pilot initiatives are integrated into the recommendations to help guide site conversion and trial design.</p><p><strong>Discussion: </strong>Phase 1 teletrials are a necessary evolution in clinical trial conduct, driven by increasing demands for equitable access to life-saving therapies. Challenges, including resource-intensive set-up, cost management, and oversight requirements, are acknowledged. However, with proper planning and stakeholder collaboration, teletrials offer significant benefits: increased trial recruitment, improved R/R patient access, and reduced geographic disparities. The expansion of teletrials will be crucial for meeting the recruitment challenges posed by biomarker-driven and rare-disease studies while maintaining safety and scientific integrity.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14202"},"PeriodicalIF":1.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of Prognosis and Immunological Features in Hepatocellular Carcinoma Based on Non-Apoptotic Regulatory Cell Death Genes.","authors":"Yefeng Yao, Songjie Wu, Yilin Leiyang, Mengying Li","doi":"10.1111/ajco.14204","DOIUrl":"https://doi.org/10.1111/ajco.14204","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is the most common liver cancer. Exploring non-apoptotic regulated cell death (RCD) offers a strategy to overcome drug resistance. This study investigates a risk model based on non-apoptotic RCD-related genes to predict clinical outcomes and guide immunotherapy.</p><p><strong>Methods: </strong>We identified genes associated with non-apoptotic RCD in HCC through weighted gene co-expression network analysis (WGCNA) and differential analysis. We then employed non-negative matrix factorization (NMF) clustering to categorize HCC into molecular subtypes related to non-apoptotic RCD and identified differentially expressed genes (DEGs) among these subtypes. We developed a prognostic model utilizing Cox regression and LASSO analysis, stratifying patients into specific risk groups and validating the model's prognostic significance. We subsequently analyzed immune functions and tumor mutation burden (TMB). Finally, we identified potential drugs and evaluated drug sensitivity specific to HCC.</p><p><strong>Results: </strong>We identified four non-apoptotic RCD genes and classified patients into three subtypes. We observed significant differences in immune characteristics and prognostic outcomes among these groups. Six DEGs emerged as key indicators for risk assessment, leading to a prognostic model. High-risk patients face poorer survival rates and increased mortality. Independent prognostic analyses confirm that these models can effectively predict patient outcomes. Notably, in high-risk patients, immune-related functions appear suppressed, facilitating tumor immune evasion.</p><p><strong>Conclusion: </strong>We developed a risk model focused on non-apoptotic RCD genes. This model accurately predicts the prognosis for HCC patients. It may also offer new insights for clinical decisions and immunotherapy.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14204"},"PeriodicalIF":1.4,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individualized T3-4N+ Rectal Cancer Treatment Strategies: Exploring the Efficacy of Preoperative Synchronized Lateral Lymph Node Simultaneous Integrated Boost Radiation Therapy.","authors":"Xinjue Shi, Siyao Zhong, Xianbin Zheng, Xianxiu Nan, Xuan Liu, Qiteng Liu, Jing Yuan, Yuyan Gao","doi":"10.1111/ajco.14199","DOIUrl":"https://doi.org/10.1111/ajco.14199","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to assess the impact of preoperative synchronized lateral lymph node simultaneous integrated boost radiation therapy on the prognosis of T3-4N+ rectal cancer patients.</p><p><strong>Methods: </strong>A retrospective analysis was performed on 35 patients with rectal cancer from Beijing Luhe Hospital affiliated to Capital Medical University from August 1, 2019 to April 30, 2023, including 22 patients with T3-4N+ rectal cancer, all of whom received the above preoperative therapy: planning gross tumor volume (PGTV): 95% PGTV 55 Gy/2.2 Gy/25 times; planning gross tumor volume of node (PGTVnd): 95% PGTVnd 60 Gy/2.4 Gy/25 times; and planning target volume (PTV): 95% PTV 50 Gy/2 Gy/25 times. Total mesorectal excision (TME) was performed 8-12 weeks after the radiotherapy. The primary endpoints were postoperative pathologic complete response (pCR) rate, downstaging rate, and 1-, 2-, and 3-year local regional recurrence-free survival (LRRFS). The secondary endpoints were anal retention rate, 1-, 2-, and 3-year event-free survival (EFS), overall survival (OS) rates, treatment-emergent adverse events (TEAEs), and perioperative complications.</p><p><strong>Results: </strong>All 22 patients completed treatment, with pCR rate of 22.7% (5/22), anal preservation rate of 77.3% (17/22), tumor downstaging (T-downstaging) rate of 95.5% (21/22), and nodal downstaging (N-downstaging) rate of 100% (22/22), and 1-year postoperative LRRFS, EFS, and OS rates of 100%, 80%, and 86%, respectively; 2-year LRRFS, EFS, and OS rates of 90%, 63%, and 75%, respectively; and 3-year LRRFS, EFS, and OS rates of 90%, 63%, and 63%, respectively. Only two cases of Grade 3 adverse events occurred, which were clinically manageable and did not require permanent treatment cessation.</p><p><strong>Conclusion: </strong>This retrospective analysis demonstrated encouraging short-term outcomes, including a 22.7% pCR rate and a 3-year LRRFS of 90%, with manageable toxicity. Nonetheless, these findings should be interpreted with caution due to the limited sample size and absence of a control arm.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14199"},"PeriodicalIF":1.4,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}